AGE · Agex Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $130.0K | $0 | - | $14.0K | $51.0K | $5.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.20M | - | $3.65M | $3.15M | $2.95M | - | $2.42M | $1.59M | $1.11M | - |
| SG&A | $3.08M | - | $2.74M | $2.54M | $2.91M | - | $2.91M | $2.32M | $1.22M | - |
| Total Operating Expenses | $6.28M | - | $6.39M | $5.70M | $5.86M | - | $5.33M | $3.92M | $2.33M | - |
| D&A | $0 | - | $0 | $0 | $17.0K | - | - | $24.0K | $25.0K | - |
| Operating Income | ($6.89M) | - | ($6.39M) | ($5.57M) | ($5.86M) | - | ($5.31M) | ($3.87M) | ($2.32M) | - |
| Interest Expense | $189.0K | - | $6.0K | $9.0K | $186.0K | - | $100.0K | $242.0K | $99.0K | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.90M) | - | ($4.58M) | ($6.45M) | ($4.81M) | - | $1.41M | $5.20M | ($9.44M) | - |
| EPS - Basic | ($0.58) | - | ($0.45) | ($0.66) | ($0.49) | - | $0.16 | $0.61 | ($3.38) | - |
| EPS - Diluted | ($0.58) | - | ($0.45) | ($0.66) | ($0.49) | - | $0.13 | $0.51 | ($3.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.53M | $3.06M | $8.62M | $6.04M | $4.27M | $3.67M | $3.19M | $6.06M | $8.71M | $345.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | $65.0K | $57.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.83M | $1.93M | $2.73M | $1.71M | $1.19M | $744.0K | - | $1.20M | $2.60M | $1.41M |
| Current Assets | $26.47M | $6.08M | $11.50M | $7.99M | $5.75M | $5.68M | $5.42M | $8.92M | $8.94M | $754.0K |
| Total Assets | $27.30M | $6.95M | $12.41M | $8.94M | $6.73M | $6.72M | $7.43M | $10.71M | $10.86M | $11.96M |
| Current Liabilities | $6.34M | $3.56M | $8.79M | $3.56M | $2.35M | $2.37M | $13.51M | $12.63M | $14.06M | $5.91M |
| Long-term Debt | - | - | - | - | - | - | $11.15M | - | - | - |
| Total Liabilities | $9.67M | $6.99M | $10.82M | $7.29M | $5.17M | $6.22M | $21.26M | $27.10M | $15.16M | $6.61M |
| Stockholders' Equity | $17.63M | ($37.0K) | $1.76M | $1.80M | $1.70M | $641.0K | ($13.77M) | ($16.36M) | ($4.31M) | $5.47M |
| Retained Earnings | ($70.40M) | ($63.50M) | ($60.16M) | ($55.58M) | ($49.13M) | ($44.32M) | ($21.77M) | ($23.18M) | ($5.43M) | ($131.01M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.57M) | - | - | - | ($4.32M) | - | - | - | ($1.58M) | - |
| Investing Cash Flow | ($25.0K) | - | - | - | $0 | - | - | - | ($14.0K) | - |
| Financing Cash Flow | $26.06M | - | - | - | $4.92M | - | - | - | $2.73M | - |
| CapEx | $25.0K | - | - | - | $0 | - | - | - | $14.0K | - |
| Free Cash Flow | ($4.59M) | - | - | - | ($4.32M) | - | - | - | ($1.59M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -4280.8% | - | - | -37942.9% | -7580.4% | -46420.0% | - |
| EBITDA margin | - | - | - | -4280.8% | - | - | - | -7533.3% | -45920.0% | - |
| Net margin | - | - | - | -4960.0% | - | - | 10071.4% | 10203.9% | -188740.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -31820.0% | - |
| FCF / Net income | 0.67 | - | - | - | 0.90 | - | - | - | 0.17 | - |
| R&D / Revenue | - | - | - | 2424.6% | - | - | 17250.0% | 3125.5% | 22120.0% | - |
| SG&A / Revenue | - | - | - | 1956.2% | - | - | 20792.9% | 4554.9% | 24400.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.3% | - | -36.9% | -72.1% | -71.5% | - | 19.0% | 48.6% | -86.9% | - |
| Return on equity | -39.1% | - | -260.5% | -357.8% | -283.0% | - | -10.2% | -31.8% | 219.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.18 | 1.71 | 1.31 | 2.24 | 2.45 | 2.40 | 0.40 | 0.71 | 0.64 | 0.13 |
| Quick ratio | 4.18 | 1.71 | 1.31 | 2.24 | 2.45 | 2.40 | 0.40 | 0.71 | 0.64 | 0.13 |
| Cash ratio | 3.87 | 0.86 | 0.98 | 1.70 | 1.81 | 1.55 | 0.24 | 0.48 | 0.62 | 0.06 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | -0.81 | - | - | - |
| Debt / Assets | - | - | - | - | - | - | 1.50 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.5x | - | -1065.3x | -618.3x | -31.5x | - | -53.1x | -16.0x | -23.4x | - |
| Equity multiplier | 1.55 | -187.86 | 7.05 | 4.96 | 3.96 | 10.49 | -0.54 | -0.65 | -2.52 | 2.19 |
| Liabilities / Assets | 0.35 | 1.01 | 0.87 | 0.82 | 0.77 | 0.92 | 2.86 | 2.53 | 1.40 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.01 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | 4745d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -100.0% | 154.9% | -100.0% | - | -79.1% | 466.7% | -50.0% | - |
| Revenue CAGR (3y) | - | - | - | 121.3% | - | - | -16.4% | 11.3% | -55.3% | - |
| Revenue CAGR (5y) | - | - | - | -20.7% | - | - | -49.1% | -33.1% | -53.9% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -17.6% | - | -20.3% | -43.9% | -152.4% | - | -125.5% | -105.0% | -7.6% | - |
| Net income growth (YoY) | -43.3% | - | - | - | 49.0% | - | - | - | -188.0% | - |
| EPS growth (YoY) | -18.4% | - | - | - | 85.5% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -6.3% | - | - | - | -171.7% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 936.3% | - | - | - | - | -88.3% | 50.0% | 26.2% | 78.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$130.0K totalReportable Segment$130.0K · 100.0%
Product / service
$130.0K totalGrant Revenues$130.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AgeX Therapeutics against the 5 most active filers in the same SIC group.